ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives $8.50 Consensus PT from Analysts

ALX Oncology Holdings Inc. (NASDAQ:ALXO) has received an average rating of “Moderate Buy” from the six brokerages that are covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $8.50.

Several research analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of ALX Oncology in a research report on Wednesday, December 18th. Cantor Fitzgerald reiterated an “overweight” rating on shares of ALX Oncology in a research note on Wednesday, December 18th. Finally, Jefferies Financial Group lowered ALX Oncology from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $12.00 to $2.00 in a report on Thursday, December 19th.

Insider Buying and Selling

In other ALX Oncology news, Director Rekha Hemrajani purchased 30,000 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was acquired at an average cost of $1.55 per share, for a total transaction of $46,500.00. Following the purchase, the director now directly owns 33,000 shares of the company’s stock, valued at $51,150. This trade represents a 1,000.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 33.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On ALX Oncology

Large investors have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. purchased a new stake in ALX Oncology in the 2nd quarter worth $1,834,000. GSA Capital Partners LLP acquired a new position in ALX Oncology in the 3rd quarter valued at about $88,000. Marshall Wace LLP increased its stake in ALX Oncology by 423.0% during the 2nd quarter. Marshall Wace LLP now owns 635,679 shares of the company’s stock worth $3,833,000 after buying an additional 514,133 shares during the period. SG Americas Securities LLC raised its stake in shares of ALX Oncology by 33.6% in the third quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock valued at $50,000 after acquiring an additional 6,888 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of ALX Oncology by 394.8% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock valued at $39,000 after buying an additional 5,200 shares during the period. 97.97% of the stock is currently owned by institutional investors.

ALX Oncology Trading Down 2.1 %

Shares of ALXO stock opened at $1.83 on Monday. The stock’s fifty day simple moving average is $1.51 and its 200 day simple moving average is $3.14. The company has a quick ratio of 4.82, a current ratio of 4.82 and a debt-to-equity ratio of 0.07. ALX Oncology has a twelve month low of $1.19 and a twelve month high of $17.83. The firm has a market capitalization of $96.52 million, a P/E ratio of -0.61 and a beta of 1.04.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.